AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27013640 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus metronidazole (MTZ) 400 mg TID and amoxicillin (AMX) 500 mg TID for 14 days
Number of subjects: 58
Study 27013640 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) only
Number of subjects: 58
Study 27013640 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus metronidazole (MTZ) and amoxicillin (AMX)
Number of subjects: 58
Study 27013640 — intervention group
Group type: EXPERIMENTAL
Intervention: MTZ + AMX intake
Number of subjects: 58
Study 25012289 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 329993 (ISIS‐CRPR x) at 400 mg
Number of subjects: 30
Study 25012289 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 329993 (ISIS‐CRPR x) at 600 mg
Number of subjects: 30
Study 25012289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22449293 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily)
Number of subjects: 4832
Study 22449293 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months
Number of subjects: 4832
Study 22449293 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 4832
Study 22449293 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 4832
Study 21104507 — intervention group
Group type: EXPERIMENTAL
Intervention: AlcoholEdu for College 8.0 (online alcohol course)
Number of subjects: 1620
Study 21104507 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 1620
Study 18455592 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass grafting
Number of subjects: 50
Study 18455592 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 50
Study 18455592 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac troponin I
Number of subjects: 50
Study 18455592 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart-type fatty acid-binding protein
Number of subjects: 50
Study 18455592 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased cardiac troponin I levels (>0.92 ng/mL)
Number of subjects: 50
Study 18455592 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased heart-type fatty acid-binding protein levels (>6.8 ng/mL)
Number of subjects: 50
Study 15994267 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (FP)
Number of subjects: 31
Study 15994267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 15994267 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroids (FP)
Number of subjects: 31
Study 12363064 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine
Number of subjects: 60
Study 12363064 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 60
Study 12363064 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 60
Study 12363064 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 60
Study 12363064 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 9972993 — intervention group
Group type: EXPERIMENTAL
Intervention: SLAM
Number of subjects: 0
Study 9972993 — intervention group
Group type: EXPERIMENTAL
Intervention: SLEDAI
Number of subjects: 0
Study 9972993 — intervention group
Group type: EXPERIMENTAL
Intervention: BILAG
Number of subjects: 0
Study 9972993 — intervention group
Group type: EXPERIMENTAL
Intervention: ECLAM
Number of subjects: 0
Study 9972993 — intervention group
Group type: EXPERIMENTAL
Intervention: SIS
Number of subjects: 0
Study 9972993 — intervention group
Group type: EXPERIMENTAL
Intervention: SLICC/ACR Damage Index (SDI)
Number of subjects: 0
Study 9972993 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-20
Number of subjects: 0
Study 9972993 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 0
Study 7564341 — intervention group
Group type: EXPERIMENTAL
Intervention: mexiletine
Number of subjects: 16
Study 7564341 — intervention group
Group type: EXPERIMENTAL
Intervention: aprindine
Number of subjects: 16
Study 7564341 — intervention group
Group type: EXPERIMENTAL
Intervention: disopyramide
Number of subjects: 16
Study 7564341 — intervention group
Group type: EXPERIMENTAL
Intervention: pilsicainide
Number of subjects: 16
Study 1907840 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lithium carbonate (500 mg)
Number of subjects: 6
Study 6778757 — intervention group
Group type: EXPERIMENTAL
Intervention: hypertonic glucose alone (49.2 +/- 7.9 kcal/kg day)
Number of subjects: 16
Study 6778757 — intervention group
Group type: COMPARATOR
Intervention: intravenous fat emulsion (60% of the nonprotein energy) in addition to hypertonic glucose (51.5 +/- 5.0 kcal/kg/day)
Number of subjects: 16
Study 31820604 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint stimulation (auricular point pressing with magnetic beads and transcutaneous electrical acupoint stimulation at bilateral Hegu and Neiguan)
Number of subjects: 62
Study 31820604 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint stimulation
Number of subjects: 62
Study 31820604 — intervention group
Group type: COMPARATOR
Intervention: Control group (medical adhesive plaster with no stimulation)
Number of subjects: 62
Study 28561216 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention consisting of 5 sessions covering topics such as disclosure of diagnosis and legal frameworks.
Number of subjects: 0
Study 28561216 — intervention group
Group type: COMPARATOR
Intervention: Control group received treatment as usual.
Number of subjects: 0
Study 27474496 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (videotapes of EOL and ED encounters)
Number of subjects: 72
Study 27474496 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 27474496 — intervention group
Group type: EXPERIMENTAL
Intervention: Online course usage
Number of subjects: 72
Study 24684103 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with general anesthesia (GA)
Number of subjects: 160
Study 24684103 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 160
Study 22909343 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg after each haemodialysis session
Number of subjects: 50
Study 22909343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg daily
Number of subjects: 50
Study 22909343 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin and Pregabalin
Number of subjects: 50
Study 19732370 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (anti-IgE)
Number of subjects: 221
Study 19732370 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 221
Study 17566639 — intervention group
Group type: EXPERIMENTAL
Intervention: TmLRP‐TT
Number of subjects: 100
Study 17566639 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 100
Study 17566639 — intervention group
Group type: EXPERIMENTAL
Intervention: TmLRP‐TT and TURP
Number of subjects: 100
Study 15956789 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified allergen vaccine (maximum concentration 990 mug/ml, 100 times the maximum dose of native extract)
Number of subjects: 35
Study 15956789 — intervention group
Group type: COMPARATOR
Intervention: Unmodified allergen extract (maximum concentration 70 mug/ml, potency 10 HEP(L)/ml)
Number of subjects: 35
Study 12527147 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week intervention based on stages of change
Number of subjects: 316
Study 12527147 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 316
Study 10802462 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 50
Study 9148259 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG capsulotomy
Number of subjects: 75
Study 9148259 — intervention group
Group type: COMPARATOR
Intervention: Intact posterior capsule
Number of subjects: 75
Study 1517787 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐epi‐doxorubicin plus cisplatin
Number of subjects: 157
Study 1517787 — intervention group
Group type: COMPARATOR
Intervention: 4‐epi‐doxorubicin alone
Number of subjects: 157
Study 6206578 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation with bleomycin or vinblastine or a combination of both
Number of subjects: 272
Study 6206578 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger radiation fraction and shorter treatment time schedule
Number of subjects: 272
Study 6206578 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation with chemotherapy
Number of subjects: 272
Study 6206578 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochemotherapy
Number of subjects: 272
Study 6206578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngostomy tube
Number of subjects: 272
Study 30545282 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth Education Program (TEP)
Number of subjects: 107
Study 30545282 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 107
Study 28505227 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (500 mg/d) with exercise
Number of subjects: 30
Study 28505227 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 30
Study 26868063 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 60
Study 26868063 — intervention group
Group type: COMPARATOR
Intervention: Intravenous iron sucrose (ISC)
Number of subjects: 60
Study 25017619 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia (SZ) patients
Number of subjects: 60
Study 25017619 — intervention group
Group type: COMPARATOR
Intervention: Bipolar disorder (BD) patients
Number of subjects: 60
Study 23008078 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic lecture
Number of subjects: 60
Study 23008078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture plus case discussion
Number of subjects: 60
Study 23008078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture plus small-group training
Number of subjects: 60
Study 23008078 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 60
Study 19608703 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate supplementation
Number of subjects: 134
Study 17241249 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 200 mg three times a day for 3 days
Number of subjects: 322
Study 17241249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 15458569 — intervention group
Group type: EXPERIMENTAL
Intervention: Metadate CD 20 mg
Number of subjects: 0
Study 15458569 — intervention group
Group type: EXPERIMENTAL
Intervention: Metadate CD 40 mg
Number of subjects: 0
Study 15458569 — intervention group
Group type: COMPARATOR
Intervention: Concerta 18 mg
Number of subjects: 0
Study 15458569 — intervention group
Group type: COMPARATOR
Intervention: Concerta 36 mg
Number of subjects: 0
Study 10703815 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic monoclonal antibodies (mAb)
Number of subjects: 0
Study 8894485 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline proinsulin levels
Number of subjects: 87
Study 8894485 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline fasting glucose levels
Number of subjects: 87
Study 8894485 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 2-h glucose levels
Number of subjects: 87
Study 8894485 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline fasting C-peptide levels
Number of subjects: 87
Study 8894485 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline intra-abdominal fat area
Number of subjects: 87
Study 8894485 — intervention group
Group type: EXPERIMENTAL
Intervention: Disproportionate hyperproinsulinaemia
Number of subjects: 87
Study 1565535 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 60
Study 1565535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3935343 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) 20 mg
Number of subjects: 24
Study 3935343 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (5 mg)
Number of subjects: 24
Study 3935343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29289554 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg Testosterone + 50 mg Sildenafil
Number of subjects: 497
Study 29289554 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg Testosterone + 10 mg Buspirone
Number of subjects: 497
Study 26569055 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic nerve-sparing radical hysterectomy (LNSRH)
Number of subjects: 106
Study 26569055 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic radical hysterectomy (LRH)
Number of subjects: 106
Study 23558873 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 1200 mg every 12 hours with a high-fat meal
Number of subjects: 20
Study 23558873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20388644 — intervention group
Group type: EXPERIMENTAL
Intervention: Active guideline implementation
Number of subjects: 0
Study 20388644 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18004577 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated implantation technique
Number of subjects: 64
Study 18004577 — intervention group
Group type: COMPARATOR
Intervention: Conventional implantation technique
Number of subjects: 64
Study 15713143 — intervention group
Group type: EXPERIMENTAL
Intervention: C. pneumoniae antibodies (IgG, IgA, IgM) measured using a solid‐phase enzyme immunoassay
Number of subjects: 91
Study 15713143 — intervention group
Group type: EXPERIMENTAL
Intervention: C. pneumoniae antibodies (IgA, IgM)
Number of subjects: 91
Study 15713143 — intervention group
Group type: EXPERIMENTAL
Intervention: C. pneumoniae antibodies
Number of subjects: 91
Study 12522361 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube introducer (ETTI)
Number of subjects: 51
Study 12522361 — intervention group
Group type: COMPARATOR
Intervention: Standard orotracheal intubation (SOTI)
Number of subjects: 51
Study 10711877 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 9
Study 10711877 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 9
Study 8610795 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol hemihydrate 0.25%
Number of subjects: 371
Study 8610795 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.25%
Number of subjects: 371
Study 8610795 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol hemihydrate 0.5%
Number of subjects: 371
Study 8610795 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5%
Number of subjects: 371
Study 8610795 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol hemihydrate (0.25% and 0.5%)
Number of subjects: 371
Study 8610795 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate (0.25% and 0.5%)
Number of subjects: 371
Study 1477848 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg single oral dose)
Number of subjects: 9
Study 1477848 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (120 mg daily for 2 weeks)
Number of subjects: 9
Study 1477848 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (240 mg daily for 2 weeks)
Number of subjects: 9
Study 3982837 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 48
Study 3982837 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mock TNS)
Number of subjects: 48
Study 31364209 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management (CDSM) program
Number of subjects: 420
Study 31364209 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 420
Study 27759614 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic surgical system (Levita Magnetics' Surgical System) used during a 3-port laparoscopic technique
Number of subjects: 50
Study 27787387 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin add-on therapy to continuous subcutaneous insulin infusion (CSII)
Number of subjects: 69
Study 27787387 — intervention group
Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 69
Study 24804913 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured ward round training (Intervention Group, IG; n=18) during an eight-week training course.
Number of subjects: 36
Study 24804913 — intervention group
Group type: COMPARATOR
Intervention: On-ward training regarding how to take patient histories and perform physical examinations (Control Group, CG; n=18).
Number of subjects: 36
Study 22563952 — intervention group
Group type: COMPARATOR
Intervention: Acamprosate treatment
Number of subjects: 0
Study 20132142 — intervention group
Group type: EXPERIMENTAL
Intervention: Melbourne Assessment of Unilateral Upper Limb Function (MUUL)
Number of subjects: 70
Study 20132142 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisting Hand Assessment (AHA)
Number of subjects: 70
Study 20132142 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereognosis
Number of subjects: 70
Study 20132142 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength
Number of subjects: 70
Study 20132142 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory measures
Number of subjects: 70
Study 20132142 — intervention group
Group type: COMPARATOR
Intervention: Comparison with typically developing children
Number of subjects: 70
Study 17945260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (IVMP) pulses (1 g/day for 5 days with an oral prednisone taper, every 4 months for 3 years, then every 6 months for 2 years)
Number of subjects: 88
Study 17945260 — intervention group
Group type: COMPARATOR
Intervention: IVMP only for relapses (1 g/day for 5 days with an oral prednisone taper)
Number of subjects: 88
Study 19390550 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study 15063963 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus Clomiphene Citrate (CC)
Number of subjects: 21
Study 15063963 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene Citrate (CC) alone
Number of subjects: 21
Study 11343406 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of facial features in adults
Number of subjects: 0
Study 11343406 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted salience of facial features
Number of subjects: 0
Study 11343406 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted Fuzzy Logical Model of Perception
Number of subjects: 0
Study 11343406 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental differences in face identification
Number of subjects: 0
Study 11343406 — intervention group
Group type: EXPERIMENTAL
Intervention: Information used for face identification
Number of subjects: 0
Study 9222709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg daily and clarithromycin 500 mg b.i.d. (PC)
Number of subjects: 250
Study 9222709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg daily, clarithromycin 500 mg b.i.d. plus amoxicillin 1 g b.i.d. (PCA)
Number of subjects: 250
Study 9222709 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subcitrate 120 mg t.i.d., roxithromycin 150 mg b.i.d., metronidazole 250 mg b.i.d. plus ranitidin 300 mg (BRMR)
Number of subjects: 250
Study 8236398 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular quinine (20 mg/kg followed by 10 mg/kg every 8 h)
Number of subjects: 104
Study 8236398 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine (20 mg/kg followed by 10 mg/kg every 8 h)
Number of subjects: 104
Study 3522030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 0
Study 3522030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 0
Study 3522030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 0
Study 3522030 — intervention group
Group type: COMPARATOR
Intervention: Aluminum ibuprofen 400 mg
Number of subjects: 0
Study 3522030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11777644 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous Integrated Boost (SIB) technique
Number of subjects: 5
Study 11777644 — intervention group
Group type: COMPARATOR
Intervention: Sequential Boost technique
Number of subjects: 5
Study 31368135 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway group (electronic clinical pathway management)
Number of subjects: 264
Study 31368135 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine blood glucose control treatment)
Number of subjects: 264
Study 30451141 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up intervention
Number of subjects: 515
Study 30451141 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 515
Study 27456299 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-containing dressings
Number of subjects: 613
Study 27456299 — intervention group
Group type: COMPARATOR
Intervention: Non-chlorhexidine control dressings
Number of subjects: 613
Study 24552795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI) applied for 1 randomly assigned leg after each training session, consisting of 3 4-minute intervals with a 30-second rest period
Number of subjects: 17
Study 24552795 — intervention group
Group type: COMPARATOR
Intervention: Control leg (not cooled)
Number of subjects: 17
Study 23061606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive facial exercises for 5 minutes after the first and third botulinum toxin-A treatment
Number of subjects: 26
Study 23061606 — intervention group
Group type: COMPARATOR
Intervention: Rest in a seated position for 5 minutes after the second treatment (control group)
Number of subjects: 26
Study 23061606 — intervention group
Group type: EXPERIMENTAL
Intervention: Squeezing exercises after the second treatment (Group B)
Number of subjects: 26
Study 20305329 — intervention group
Group type: EXPERIMENTAL
Intervention: Clebopride
Number of subjects: 81